Viking Therapeutics, Inc.

NASDAQ:VKTX

Biotechnology

Healthcare
$26.17 +1.06%

+$0.32 today

Market cap
$3.34B
Beta
0.68
P/E (TTM)
-7.5
EPS (TTM)
-$4.09
52W Low $22.96High $43.15

Volume 2.87M

Average 2.20M

VKTX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Viking Therapeutics, Inc.NASDAQ: VKTX

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 271.2% from a year ago

Cash & equivalents stood at $125.75M at the end of Q2 FY2026, up 271.2% from a year earlier and up 6.5% from the prior quarter. Over 3 fiscal years it compounded at +65.4% a year.

Context

  • Cash & equivalents amounted to 24.1% of total assets at the end of Q2 FY2026, up 20.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +271.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$125.75M+6.5% QoQ
Last fiscal yearDec 2025
$165.81M+521.6% YoY
Year agoJun 2025
$33.88M+271.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+271.2%——
1 year+521.6%——
3-year CAGR+65.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
165.81M USD
Year-over-year change
+521.6%
4-year CAGR
+58.4%

Cash & Equivalents vs competitors

How VKTX compares with its peers on the latest reported figures

  • VKTX's Jun 2026 cash & equivalents of $125.75M is the 6th highest of the 7 companies compared; the peer median is $164.41M.
  • Its year-over-year change of +271.2% is the highest of 6, against a peer median of -24.8%.
  • Cash & equivalents amounts to 24.1% of total assets for VKTX, versus a peer median of 29.6%.
VKTX Competitors Peer median
Cash & Equivalents for VKTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$424.15M -24.8%+1.6%60.2%
MDGLMadrigal Pharmaceuticals, Inc.Jun 2026$292.73M +57.2%-15.7%23.5%
SEPNSepterna, Inc.Sep 2026$167.12M -47.8%+58.0%27.0%
MBXMBX Biosciences, Inc. Common StockSep 2026$161.69M -27.5%+46.0%32.3%
KLRAKailera Therapeutics, Inc.Jun 2026$130.3M ——10.8%
VKTXViking Therapeutics, Inc.Jun 2026$125.75M +271.2%+65.4%24.1%
VTVTvTv Therapeutics Inc.Mar 2026$98.09M +215.8%+94.3%99.3%
Peer median (excluding VKTX) $164.41M-24.8%+46.0%29.6%

Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents26.37M36.63M55.52M26.68M165.81M
Short-term Investments175.73M118.85M306.56M875.94M539.93M
Net Receivables00000
Inventory00000
Other Current Assets7.81M8.14M2.52M1.13M1.81M
Total Current Assets210.53M167.04M367.23M907.22M715.6M
Property, Plant & Equipment (Net)25K1.42M1.13M1M85K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets109K71K139K102K46K
Total Non-current Assets134K1.49M1.27M1.11M131K
Total Assets210.66M168.53M368.49M908.32M715.73M
Account Payables1.44M8.53M7.51M9.81M53.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities8.78M21.95M19.14M27.41M76.67M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities01.26M936K630K0
Total Liabilities8.78M23.21M20.07M28.04M76.67M
Common Stock1K1K1K1K1K
Retained Earnings(223.18M)(292.05M)(377.94M)(487.91M)(847.55M)
Accumulated OCI(549K)(1.1M)(389K)(788K)378K
Other Stockholders Equity00000
Minority Interest00000
Total Equity201.88M145.32M348.42M880.28M639.06M
Total Debt29K1.56M1.26M1.12M137K
Net Debt(26.34M)(35.07M)(54.26M)(25.56M)(165.67M)

Viking Therapeutics, Inc.

NASDAQ:VKTX

Intrinsic Alpha fair value

Locked

Current Price

$26.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.